Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three ...

Researchers report the impact of sparsentan vs irbesartan on proteinuria in patients with focal segmental glomerulosclerosis.

LightPath Technologies, Inc. ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today ...

SenesTech, Inc. , the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Controltm products, will report financial results for its ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

"I’m attending so that I can be seen and heard,” said AKF Ambassador Ashli Littleton, who lives in Clarksville, Tennessee and is attending the Kidney Action Summit for the first time. "We have to be ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

Travere Therapeutics TVTX posted a profit for the first quarter on Monday. The company reported quarterly earnings of 5 cents ...

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?